Captain T Cell Secures Seed Financing Round Totaling € 8.5 Million
Summary
Felix Lorenz, CEO of Captain T Cell, said: This successful financing round allows us to accelerate our high-potential therapies and brings us closer to providing life-saving options for patients underserved by current treatments. We are steadfast in our mission to progress our lead candidate towards the clinic and to establish our TCR-ALLO platform as a leader in off-the-shelf solid tumor therapeutics.We have been following the Captain T Cell team for some time and have been impressed by their scientific depth and management capabilities. Captain T Cell has the potential to become a global leader in the development of novel oncology drugs, said Dr. Jaromir Zahr\xe1dka, Managing Partner of i&i Bio.T cell-based immunotherapies represent a powerful tool in the challenging fight against solid tumors. For more information, please visit i&i Bio is a Luxembourg-based venture capital firm that invests in innovative European life sciences companies focused on drug discovery, medical devices, diagnostics, and digital health. The objective of EGF is to respond to the economic impact of the COVID-19 pandemic by ensuring that companies in the Participating Member States have sufficient short-term liquidity available to weather the crisis and are able to continue their growth and development in the medium to long-term.More information can be found .Brandenburg Kapital GmbH is a subsidiary of the Investitionsbank des Landes Brandenburg (ILB).